ArticleInternational journal of technology assessment in health care2026
What is new in the early health technology assessment's new definition?
Article in International journal of technology assessment in health care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early health technology assessment (HTA) has recently been defined as a process for evaluating the "potential value" of technologies at early development stages. This analysis examines how value is characterized in early stages compared to standard HTA. Using the MAPS framework (Methods, Attributes, Procedures, and Social Preferences), the findings indicate that a broader value framework may be applicable to early HTA relative to standard HTA. This framework includes systematic consideration of attributes beyond health-related benefits, such as real option value and innovation, as well as additional methods like fiscal impact analysis and social return on investment. Additionally, there is potential for less variation in early HTA processes globally, given that these assessments are less tied to local funding decisions. Finally, the role of social preferences in early HTA may also involve considering trade-offs and impact modifiers that are particularly relevant in initial stages, and which deserve further research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.